logo
Share SHARE
FONT-SIZE Plus   Neg

Bristol-Myers Reports Positive Results From Study On Cancer Drug

Bristol-Myers Squibb Company (BMY: Quote) Saturday said an experimental drug showed positive results in patients suffering from melanoma, kidney cancer and lung cancer in a preliminary clinical trial.

Results of the Phase-I study on anti-PD-1 or BMS-936558 in patients with previously-treated non small-cell lung cancer, metastatic melanoma and renal cell carcinoma were encouraging as they showed improvement in patients. The clinical trial added to the understanding of the potential of immuno-oncology as a therapeutic approach in the treatment of cancer, the pharmaceutical firm said.

"Immuno-oncology is a prioritized area of research and development at Bristol-Myers Squibb and we plan to initiate registrational studies for anti-PD-1 in non small-cell lung cancer and renal cell carcinoma this year and late 2012, early 2013 for metastatic melanoma," Brian Daniels, senior vice president of Global Development and Medical Affairs t Bristol-Myers Squibb, said.

Anti-PD-1 is a fully-human antibody that targets the inhibitory receptor expressed on activated T-cells called PD-1 or programmed death-1.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Israeli generic drug maker Teva Pharmaceutical Industries (TEVA) on Tuesday offered to buy smaller Dutch rival Mylan N.V. (MYL) for $82 per share in cash and stock, or about $40 billion, in a bid to further tighten its grip in the global generic space. Twitter is expanding its direct messaging feature to enable users to communicate privately with a single person or with a group of people, even if they are not following each other. High-flying Netflix may have yet another hit on its hands, as the company has ordered a spin-off of the hugely popular Full House series. Fuller House will star Candace Cameron-Bure, Jodie Sweetin and Andrea Barber, who played sisters D.J. Tanner and Stephanie Tanner, and D.J.'s bestie Kimmy Gibbler,...
comments powered by Disqus
Follow RTT